UK Medical Research Council Gap Fund: Targeted Funding for Critical Medical Product Development Steps

The MRC Gap Fund is a UKRI funding route for translation teams that are stuck at one key milestone rather than trying to fund an entire product programme. It is aimed at the single critical risk point that determines whether a promising medical concept can move toward larger, later-stage support.

This page is for people who want to know what is realistic before they spend time writing an application. It also reflects that the official page is marked as paused as of the latest published update. The practical implication is: do not assume you can submit now. Confirm the opportunity status before investing in a full draft.

At a glance

What this opportunity is designed to do

The opportunity is not for broad or piecemeal programmes. It is for one clearly defined development activity that, if successful, changes the probability of translation substantially.

In the MRC context, this sits between two known routes:

1. smaller or pump-priming development support, including IAA-type early activity
2. Gap Fund, where one defined step generates decisive translational evidence
3. larger developmental funding applications, often through the Developmental Pathway Funding Scheme

The official page frames this as a high-risk-to-next-stage bridge, where your proposal should generate data that can support a larger, more mature application or partnership. That means your application should not read like a multi-phase discovery programme. It should read like a focused experiment in decision-making.

What the grant usually supports

You can propose support for high-risk steps in areas such as:

• new small molecule medicines
• vaccines for infectious and non-infectious disease
• biologics, including antibodies, peptides and proteins
• advanced therapeutics, including gene, cell, RNA, and related modalities
• regenerative medicine
• repurposing clinical studies
• medical devices and medical imaging
• diagnostics and biomarker validation (not biomarker discovery)
• behavioural and psychological interventions
• digital healthcare and app development where AI is an enabling core technology
• surgical tools and techniques

A central requirement is that your proposal is a single-step package. The page repeatedly warns against multiple work packages or spreading the award across several disconnected actions.

Who should apply and who should not

This opportunity works best for teams with an established technical starting point, not teams at hypothesis-only stage.

You are likely a good match if

• you are based at an MRC-eligible research organisation
• you can identify one high-risk development gap and show why this one step is decisive
• your requested activity can be delivered in 6 to 18 months
• you can define explicit success criteria that decide whether to continue, pivot, or stop
• you can explain what follow-on funding, industrial partner conversation, or development pathway this step unlocks
• your budget is tightly linked to this single step

You are likely not a good match if

• your proposal is broad and contains multiple aims that can be split into separate projects
• you need major pre-clinical safety or toxicology work
• your primary task is early-phase clinical trial activity outside the narrow constraints of this route
• the project is mainly mechanism exploration with no direct product-development plan
• you want conference attendance costs funded
• you have multiple project leads in the core team application section

The page is explicit that projects with no clear route from this step to a later funding pathway or patient impact are low likelihoods.

Current eligibility logic and common exclusions

The most important eligibility points are:

• The project lead must be from a standard MRC-eligible UK organisation.
• You must actively lead and be engaged in the project.
• At most one individual should be listed as project lead, because more than one can fail application checks.
• If lead roles are internationally based there are restrictions; international involvement is possible as a co-lead in defined cases, but leadership rules apply and need explicit justification.

The page also provides explicit exclusions, including:

• work based in fundamental/investigative science without a clear translational product route
• preliminary concept generation that is better aligned to other MRC support pathways
• projects with multiple rejected versions submitted to MRC in the last 12 months
• broad mechanistic clinical programmes better suited to other funding schemes

These are not just “nice to have” notes. In practice, applications fail quickly when they ignore this boundary.

Why this route is often strategically right

Gap Fund is useful when your team is not blocked by funding volume but by a specific unknown:

• Does a prototype function in the exact expected physiological context?
• Can a data collection method reach usable sensitivity or specificity quickly enough?
• Is the proposed vector or assay platform scalable to larger efficacy-type development?
• Can the biomarker or model work robustly across expected populations?

If your team can answer these with one step, this is likely in scope.

A useful way to test fit is to write your proposal objective as one sentence:

“If we complete [specific step], then we can either proceed, pivot, or stop with evidence that protects the team from spending larger sums.”

If you can not write this sentence in plain language, the proposal is usually too broad.

How much money can be requested and where it can be spent

Award range is £50,000 to £300,000 FEC. UKRI funding is typically 80% of FEC, with 100% possible for permitted exceptions. This means your budget table must be transparent on what is requested as standard and what falls into exceptions.

The official text says you can request costs such as:

• salary contribution for project lead and co-leads
• other staff and technical support
• consumables and equipment
• data preservation, sharing and dissemination costs
• estates and indirect costs
• public contributor engagement where applicable

The page also gives specific non-fittable items:

• no conference attendance costs
• no automatic funding for IP filings or patent-related spend
• no general “bridge” between grants
• no publication cost allowance

For teams involving international elements, especially international co-leads, there is an upper limit on international costs for some country categories. If costs are from a DAC-list country, the limits differ as published on the page, and that is the section to apply.

A high-quality budget is one where each item is tied directly to the one critical step.

Project start and duration expectations

Duration is expected between 6 and 18 months, with project start typically 1 to 6 months after funding decision. This creates a planning reality: if your workflow needs long setup delays, you need to build those into the plan and still keep the timeline realistic.

A common proposal issue is writing an eight-to-twelve month timeline for a workpackage that actually requires longer recruitment, validation, or manufacturing turnarounds. Be realistic early, because timelines are judged during the approach review.

What the official application process expects

This opportunity is on the UKRI Funding Service and does not use the legacy Je-S route.

Sequence to be ready when open

1. Confirm eligibility of the lead organisation and register it in the Funding Service.
2. Start the application from the Opportunity page using the official “Start application” flow.
3. Build the draft in the Funding Service and save often.
4. Route internally to your research office for mandatory checks.
5. Return revised version and complete submission by the published deadline.

The page notes that if your organisation is not yet in the Funding Service, registration can take at least 10 working days, so teams should account for that before internal submission.

You should not assume last-minute submission is acceptable. The funding system and institutional review routes are often the first failure point.

What sections to prioritise in the form

Even if you are new to UKRI forms, the page gives enough structure to write the right core argument. The critical sections repeatedly test the same ideas:

• background and prior evidence
• how this is a single, high-risk step
• approach and study design
• team and delivery capability
• costs and resource justification
• IP strategy
• ethics and data governance

Do not treat these as separate essays. They must be connected by one core narrative.

A practical strategy:

• define the gap in one sentence
• define the step in one sentence
• define the success criteria in one sentence
• define the failure rule in one sentence
• define the next funding path in one sentence

How your proposal is assessed

The page says assessment is by the MRC DPFS panel with no external peer review comments being added as part of this process.

Assessment areas include:

• clinical or medical need
• scientific rationale
• deliverability of the work and team capability
• route-to-market and patient impact plausibility
• intellectual property strategy
• data, ethics and responsible innovation considerations

It also states a practical signal for applicants: expected failure in translational pipelines is normal, so a good proposal should still make clear what a negative or mixed result means for decision-making.

Practical read: a proposal is strongest when it is explicit about what happens in failure scenarios and why the information is still useful for future development planning.

The page also states outcomes from assessments may not be appealed. If unsuccessful, a similar application is not immediately resubmitted within 12 months of the original closing date.

If the opportunity is paused: how to use the gap period

Because the page currently states it is paused, use the pause period as preparation time instead of a reason to stop thinking about the opportunity.

• build a one-page version of your one-step thesis
• finalise a decision-tree for success and failure
• capture all partner commitments and contribution letters early
• prepare IAA context and why this is not better placed in IAA unless your institution structure requires it
• gather draft ethics, data management, TR&I and RRI notes
• align internal signing chain and research office expectations

You should be able to upload a polished version quickly if/when the next round opens.

Required materials and readiness checks

Before drafting begins, prepare the following materials:

1. Lead applicant and core team role map with one project lead.
2. Project partner list with support rationale and contribution type.
3. If including industry, readiness to complete any required industry collaboration framework requirements.
4. Clear prior funding context, including whether the host institution has IAA support or not.
5. Budget breakdown aligned to the one-step objective.
6. A minimal data management plan tied to governance and sharing expectations.
7. Evidence that ethics, animal, human participant, and risk controls are understood and addressed where relevant.

The page also makes a practical submission warning: if your project has sections that can use images, keep them minimal and keep the application self-contained. References should be included within word limits and links should be used carefully.

Common mistakes to avoid

• claiming broad product development while describing only one grant
• proposing multiple work packages
• omitting the exact decision point of the step
• weak justification for why this route is chosen over IAA/other MRC routes
• leaving required role and organisational support details vague
• missing partner letters where project partners are claimed
• over-budgets on non-permitted or non-focal costs
• ignoring SoECAT and NHS-cost attribution requirements when clinical NHS delivery is involved
• treating external collaborators as optional when they are structurally central
• submitting without institutional and technical internal review
• not stating who will do what and when

Good vs weak application style

What is evaluated positively

A strong application usually:

• explains one step in plain English
• links each method to one testable decision
• quantifies resource need by explicit deliverables
• includes a realistic failure interpretation
• gives one clear route to larger funding after success

What weak applications often look like

A weak application usually:

• stacks several high-risk activities into one narrative
• has strong science but weak translational logic
• gives no clear route after the step is completed
• overstates certainty and avoids acknowledging risk

FAQ for practical decision-making

Is this open right now?

The official page shows status as paused. Treat this as not currently open until a fresh published call window is confirmed.

Can a paused call have useful details I can use?

Yes. The rules and requirements shown remain useful for preparing your internal planning package and a rapid-response draft if the next open window appears.

Can I apply without prior MRC funding?

Yes, if other criteria are met and your host is eligible. The page allows organisations without IAA to use this route as a smaller early-stage translational step.

How many work packages are allowed?

The opportunity is explicitly single-step. Multi-package applications are repeatedly flagged as not eligible.

Can an international lead apply?

An international project co-lead is possible in specific structures, but a lead based on an international organisation is generally not allowed except for documented exceptions.

What if I do an AI-based project?

If AI is a core enabling part of the approach, you need to complete the AI-specific declaration and category response in the Funding Service.

Do we need internal support letters?

Yes, where roles and project support are claimed by the research organisation, expected support is required and should be stated accurately.

What happens if application fails?

Failure is common in high-risk translational funding, and the public guidance supports this reality. The key is whether the application provides a robust and useful decision point for the team and funders.

Step-by-step readiness before reopening

When you are ready for a likely reopen, use this sequence:

1. Confirm the opportunity is live and copy the current dates exactly.
2. Register all internal users and test funding service access.
3. Lock your single-step question and success/failure rule.
4. Prepare partner statements and roles.
5. Build the budget for standard costs and permitted exceptions.
6. Complete drafts for background, approach, team capability and data plan.
7. Run an internal read of all mandatory fields and check-word limits.
8. Submit well before institutional and system cut-off deadlines.

Do not wait for the final day to discover your institution is missing required support details.

Official links and direct contacts

• Funding opportunity page: https://www.ukri.org/opportunity/gap-fund-single-step-support-for-medical-product-development/
• Gap Fund team email: [email protected]
• MRC funding and policy email: [email protected]
• UKRI Funding Service support: [email protected]
• Funding Service phone support: 01793 547490 (Monday to Thursday 8:30-17:00, Friday 8:30-16:30)

Bottom line

The MRC Gap Fund is best for teams with one sharply defined translational bottleneck and a team that can show disciplined execution. It is not a general development grant. Do not force a full product roadmap into a single-step structure.

If the opportunity is paused, do not abandon the project. Use the pause to build a stronger, cleaner, decision-focused application package. If and when re-opened, submit only once your package is already internally aligned, because speed at reopen matters less than fit and completeness.